Compare ROAD & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | GRFS |
|---|---|---|
| Founded | 2001 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2018 | 2008 |
| Metric | ROAD | GRFS |
|---|---|---|
| Price | $113.54 | $7.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $127.80 | $10.15 |
| AVG Volume (30 Days) | ★ 1.1M | 529.9K |
| Earning Date | 05-08-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 40.46 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $785,679,000.00 | N/A |
| Revenue This Year | $27.79 | $4.49 |
| Revenue Next Year | $10.29 | $6.42 |
| P/E Ratio | $78.73 | ★ $18.67 |
| Revenue Growth | ★ 0.31 | N/A |
| 52 Week Low | $93.42 | $6.96 |
| 52 Week High | $151.00 | $10.31 |
| Indicator | ROAD | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 49.16 |
| Support Level | $108.35 | $7.64 |
| Resistance Level | $120.36 | $8.36 |
| Average True Range (ATR) | 5.31 | 0.17 |
| MACD | 1.24 | -0.04 |
| Stochastic Oscillator | 60.84 | 10.87 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.